Results 31 to 40 of about 5,495 (171)

Seizure reduction with fluoxetine in an adult woman with Dravet syndrome

Epilepsy and Behavior Case Reports, 2014
An adult woman with Dravet syndrome (documented SCN1A mutation) experienced a marked reduction in seizures when treated with the selective serotonin reuptake inhibitor (SSRI) fluoxetine.
Kimford J. Meador
doaj   +1 more source

Serotonin receptors in epilepsy: Novel treatment targets?

Epilepsia Open, 2022
Despite the availability of over 30 antiseizure medications (ASMs), there is no “one size fits it all,” so there is a continuing search for novel ASMs. There are divergent data demonstrating that modulation of distinct serotonin (5‐hydroxytryptamine, 5 ...
Jo Sourbron, Lieven Lagae
doaj   +1 more source

Resolution of Fenfluramine-associated pulmonary arterial hypertension in Lennox-Gastaut syndrome: A case report and literature review

Epilepsy & Behavior Reports
Fenfluramine is a medication originally approved for weight loss before being withdrawn for an association with the development of pulmonary arterial hypertension (PAH) and cardiac valvulopathy.
Rebecca Strafella, Richard Wang, Marissa Petchpradub, Ariel Sacknovitz, Patricia E. McGoldrick, Steven M. Wolf   +5 more
doaj   +1 more source

Fenfluramine in the treatment of developmental and epileptic encephalopathies

, 2022
: Developmental and epileptic encephalopathies are often associated with treatment resistant epilepsy. Despite the different available therapeutic options, many patients still experience a high seizure burden.
Ceulemans, Berten, Cras, Patrick, Schoonjans, An-Sofie   +2 more
core   +1 more source

Metabolism of fenfluramine to norfenfluramine in guinea-pigs

, 1988
After injection of fenfluramine into guinea-pigs, the N-dealkylated metabolite norfenfluramine was present in brain at higher concentrations and persisted longer than the parent drug, fenfluramine.
Harold D Snoddy, Kenneth W Perry, Ray W Fuller   +2 more
core   +1 more source

Effects of fenfluramine on the adrenergic system

, 1972
The influence of fenfluramine on sympathetic transmission has been examined in various intact and isolated preparations. Fenfluramine both facilitated and inhibited the responses elicited by the sympathetic stimulation according to the dose administered ...
A BONACCORSI, I PODVALOVA, P COTILLO, A BABULOVA   +3 more
core   +1 more source

Dissociation of the antiaggression and serotonin-depleting effects of fenfluramine

, 1981
Fenfluramine or norfenfluramine produced a marked and persistent depletion of whole-brain serotonin and antagonized potently the apomorphine-induced aggression response in Long Evans male rats.
G. M. McKenzie
core   +1 more source

Combinations of drugs in the Treatment of Obesity

Pharmaceuticals, 2010
Obesity is a chronic disease associated with excess morbidity and mortality. Clinical treatment, however, currently offers disappointing results, with very high rates of weight loss failure or weight regain cycles, and only two drugs (orlistat and ...
Marcio C. Mancini, Maria Edna de Melo, Cintia Cercato, Alfredo Halpern, André M. Faria, Eduardo S. L. Oliveira, Bruno Halpern   +6 more
doaj   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

Implementation and use of risk minimization control tools in the EU: A multistakeholder survey

British Journal of Clinical Pharmacology, EarlyView.
Aims This study characterized stakeholders' experiences with national implementation of risk minimization control tools (RMCTs), such as healthcare professional qualification, healthcare facility accreditation and medical intervention prior to treatment initiation, for eight medicinal products across eight European Union countries. Methods We conducted
Sharon C. M. Essink, Iris R. Joosse, Maximilian Salcher‐Konrad, Melanie Walter, Elena Deligianni, Dimitra Tsioumela, Christos Kontogiorgis, Elita Poplavska, Iluta Žīgure, Christina E. Hoeve, Teresa Leonardo Alves, Ella D. van Vliet, Renato Ferreira‐da‐Silva, Ana Kodrič, Mitja Kos, Juan Erviti, Marta Gutiérrez‐Valencia, Luis Carlos Saiz, Sofia Kälvemark Sporrong, Emelie Karlsson, Christine Leopold, Marie L. De Bruin   +21 more
wiley   +1 more source